SWOT Analysis for Viridian Therapeutics Inc

Relative Outperformance versus Industry over 1 Week
Significant (over 30%) distance from 52 week high
Rising Net Cash Flow and Cash from Operating activity
Stocks whose current price is 20% higher than week low, and more than previous close
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Companies with Low Debt
Top Gainers
Stock with Low PE (PE < = 10)
Biggest Price Gainers from Open

Stocks with Quarter Change % less than Industry
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Lowest Momentum Scores (Technical Scores)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Highest fall from 52 Week High
Low Piotroski Score : Companies with weak financials
Annual net profit declining for last 2 years
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
Recent Results: Declining Operating Profit Margin and Net Profits (YoY)
Declining profits every quarter for the past 3 quarters
RSI indicating price weakness
Stocks Underperforming their Industry Price Change in the Quarter